Clinical Development Genotype Licensing 
XTalks
APRIL 24, 2023
For rare disease studies where there is little or no clinical trial experience, outcome assessments would have to be validated within a clinical development program. Early and ongoing engagement with regulators greatly helps clinical development planning.
The Pharma Data
DECEMBER 9, 2020
The aim of the research will be to create a TGS IVD platform by optimizing a multi-layer approach encompassing the initial sample and library preparation, state-of-the-art sequencing technologies and improved genotyping procedures. Amolyt has also acquired an option to license the identified candidates for future clinical development.
Expert insights. Personalized for you.
78 
Let's personalize your content